BRIEF-Blueprint Medicines Says Expect To Achieve $2 Billion In Ayvakit Revenue By 2030

Reuters
13 Jan
BRIEF-Blueprint Medicines Says Expect To Achieve $2 Billion In Ayvakit Revenue By 2030

Jan 12 (Reuters) - Blueprint Medicines Corp BPMC.O:

  • BLUEPRINT MEDICINES PROVIDES 2025 OUTLOOK AND HIGHLIGHTS STRATEGY FOR CONTINUED GROWTH

  • BLUEPRINT MEDICINES CORP - EXPECT TO ACHIEVE $2 BILLION IN AYVAKIT REVENUE BY 2030

Source text: ID:nPn42nM2wa

Further company coverage: BPMC.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10